Trethera
Beverly Hills
About Trethera
Trethera is a biotechnology company that discovers and develops small molecules that control DNA replication and integrity.This approach is designed to overcome the limitations of single agent treatments and the associated risks of treatment failure and drug resistance. The combination therapy is addressing the alternative pathways of nucleotide biosynthesis, namely the de novo and the salvage pathways, as well as the mechanisms that protect the cancer genome against DNA replication stress and damage. The combination therapy causes an imbalance in the supply and demand of nucleotides which is lethal to cancer cells and well-tolerated by normal tissues.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $25.2M
- Last round: Grant (Dec 2025)
- Website: trethera.com
- Phone: (310)997-2788
Industries & Categories
Biotechnology, Genetics, Health Care, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/trethera-125033 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.